Advertisement

International Orthopaedics

, Volume 43, Issue 3, pp 531–538 | Cite as

Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials

  • Juan Mario García-Coronado
  • Lorena Martínez-Olvera
  • Rodrigo E. Elizondo-Omaña
  • Carlos Alberto Acosta-Olivo
  • Félix Vilchez-Cavazos
  • Luis Ernesto Simental-Mendía
  • Mario Simental-MendíaEmail author
Review Article

Abstract

Purpose

Osteoarthritis (OA) is one of the most common causes of disability and a prevalent chronic disease. The use of collagen is growing due to the satisfactory results in the treatment of OA. However, the possible beneficial effects of collagen for the treatment of OA are currently controversial. The aim of the present meta-analysis was to evaluate the effect of collagen-based supplements on OA symptoms.

Methods

PubMed-Medline, Scopus, and Google Scholar databases were searched for randomized placebo-controlled trials evaluating the effect of orally administered collagen on OA symptoms using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale and/or the Visual Analog Scale (VAS). Meta-analysis was conducted using a random-effects model and a generic inverse variance method. Heterogeneity was tested using the I2 statistic index.

Results

Collagen treatment showed a significant reduction in the score of total WOMAC index (WMD − 8.00; 95% CI − 13.04, − 2.95; p = 0.002). After subgroup analysis of the WOMAC subscores, the collagen supplementation revealed a significant decrease in the stiffness subscore (WMD − 0.41; 95% CI − 0.74, − 0.08; p = 0.01), whereas the pain (WMD − 0.22; 95% CI − 1.58, 1.13; p = 0.75) and functional limitation (WMD − 0.62; 95% CI − 5.77, 4.52; p = 0.81) subscores did not have significant differences. Finally, a significant reduction was found in the VAS score after collagen administration (WMD − 16.57; 95% CI − 26.24, − 6.89; p < 0.001).

Conclusion

The results of this meta-analysis showed that collagen is effective in improving OA symptoms by the decrease of both total WOMAC index and VAS score.

Keywords

Collagen supplementation Osteoarthritis symptoms WOMAC index Visual Analogue Scale Meta-analysis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Lane NE, Brandt K, Hawker G et al (2011) OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthr Cartil 19:478–482.  https://doi.org/10.1016/j.joca.2010.09.013 CrossRefGoogle Scholar
  2. 2.
    Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2163–2196.  https://doi.org/10.1016/S0140-6736(12)61729-2 CrossRefGoogle Scholar
  3. 3.
    Sacks JJ, Luo YH, Helmick CG (2010) Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. Arthritis Care Res 62:460–464.  https://doi.org/10.1002/acr.20041 CrossRefGoogle Scholar
  4. 4.
    Lawrence RC, Felson DT, Helmick CG et al (2008) NIH public estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part II Reva. Arthritis Rheum 58:26–35.  https://doi.org/10.1002/art.23176.Estimates CrossRefGoogle Scholar
  5. 5.
    Nelson AE, Allen KD, Golightly YM et al (2014) A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum 43:701–712.  https://doi.org/10.1016/j.semarthrit.2013.11.012 CrossRefGoogle Scholar
  6. 6.
    Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64:465–474.  https://doi.org/10.1002/acr.21596 CrossRefGoogle Scholar
  7. 7.
    Kwoh CK, Roemer FW, Hannon MJ et al (2014) Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial. Arthritis Rheumatol 66:930–939.  https://doi.org/10.1002/art.38314 CrossRefGoogle Scholar
  8. 8.
    Zegels B, Crozes P, Uebelhart D et al (2013) Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil 21:22–27.  https://doi.org/10.1016/j.joca.2012.09.017 CrossRefGoogle Scholar
  9. 9.
    Tashiro T, Seino S, Sato T et al (2012) Oral Administration of Polymer Hyaluronic Acid Alleviates Symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. Sci World J 2012:1–8.  https://doi.org/10.1100/2012/167928 CrossRefGoogle Scholar
  10. 10.
    Hussain S, Singh A, Akhtar M, Najmi AK (2017) Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. Rheumatol Int 37:1489–1498.  https://doi.org/10.1007/s00296-017-3719-0 CrossRefGoogle Scholar
  11. 11.
    Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN et al (2009) A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr 60:99–113.  https://doi.org/10.1080/09637480802498820 CrossRefGoogle Scholar
  12. 12.
    Lugo JP, Saiyed ZM, Lane NE (2016) Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J 15:14.  https://doi.org/10.1186/s12937-016-0130-8 CrossRefGoogle Scholar
  13. 13.
    Akhtar N, Haqqi TM (2012) Current nutraceuticals in the management of osteoarthritis: a review. Ther Adv Musculoskelet Dis 4:181–207.  https://doi.org/10.1177/1759720X11436238 CrossRefGoogle Scholar
  14. 14.
    Oesser S, Adam M, Babel W, Seifert J (1999) Oral administration of (14)C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). J Nutr 129:1891–1895CrossRefGoogle Scholar
  15. 15.
    Sibilla S, Godfrey M, Brewer S et al (2015) An overview of the beneficial effects of hydrolysed collagen as a nutraceutical on skin properties: scientific background and clinical studies. Open Nutraceuticals J 8:29–42.  https://doi.org/10.2174/1876396001508010029 CrossRefGoogle Scholar
  16. 16.
    Adam M (1991) WelcheWirkung Haben Gelantineparaprate? Therapie Der Osteoarthrose Therapiewoche 41:2456–2461Google Scholar
  17. 17.
    Castrogiovanni P, Trovato FM, Loreto C et al (2016) Nutraceutical supplements in the management and prevention of osteoarthritis. Int J Mol Sci 17:2042.  https://doi.org/10.3390/ijms17122042 CrossRefGoogle Scholar
  18. 18.
    Broere F, Wieten L, Klein Koerkamp EI et al (2008) Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J Immunol 181:899–906CrossRefGoogle Scholar
  19. 19.
    Müller RD, John T, Kohl B et al (2008) IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-α in human articular chondrocytes in vitro. Cytokine 44:377–385.  https://doi.org/10.1016/j.cyto.2008.10.012 CrossRefGoogle Scholar
  20. 20.
    van Meegeren MER, Roosendaal G, Jansen NWD et al (2012) IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthr Cartil 20:764–772.  https://doi.org/10.1016/j.joca.2012.04.002 CrossRefGoogle Scholar
  21. 21.
    Higgins J, Green S (2009) Cochrane handbook for systematic reviews of interventions Version 5.0.2. LondonGoogle Scholar
  22. 22.
    Kumar S, Sugihara F, Suzuki K et al (2014) A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis. J Sci Food Agric 95:702–707.  https://doi.org/10.1002/jsfa.6752 CrossRefGoogle Scholar
  23. 23.
    McAlindon TE, Nuite M, Krishnan N et al (2011) Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. Osteoarthr Cartil 19:399–405.  https://doi.org/10.1016/j.joca.2011.01.001 CrossRefGoogle Scholar
  24. 24.
    Schauss AG, Stenehjem J, Park J et al (2012) Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, biocell collagen, on improving osteoarthritis-related symptoms: a randomized, double-blind, placebo-controlled trial. J Agric Food Chem 60:4096–4101.  https://doi.org/10.1021/jf205295u CrossRefGoogle Scholar
  25. 25.
    Van Vijven JPJ, Luijsterburg PAJ, Verhagen AP et al (2012) Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Osteoarthr Cartil 20:809–821.  https://doi.org/10.1016/j.joca.2012.04.008 CrossRefGoogle Scholar
  26. 26.
    Nagler-Anderson C, Bober LA, Robinson ME et al (1986) Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A 83:7443–7446.  https://doi.org/10.1073/pnas.83.19.7443 CrossRefGoogle Scholar
  27. 27.
    Di Cesare Mannelli L, Micheli L, Zanardelli M, Ghelardini C (2013) Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskelet Disord 14:228.  https://doi.org/10.1186/1471-2474-14-228 CrossRefGoogle Scholar
  28. 28.
    Iwai K, Hasegawa T, Taguchi Y et al (2005) Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. J Agric Food Chem 53:6531–6536.  https://doi.org/10.1021/jf050206p CrossRefGoogle Scholar
  29. 29.
    Ohara H, IidaA H, Ito K et al (2010) Effects of pro-Hyp, a collagen hydrolysate-derived peptide, on hyaluronic acid synthesis using in vitro cultured synovium cells and Oral ingestion of collagen hydrolysates in a Guinea pig model of osteoarthritis. Biosci Biotechnol Biochem 74:2096–2099.  https://doi.org/10.1271/bbb.100193 CrossRefGoogle Scholar
  30. 30.
    Oesser S, Seifert J (2003) Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res 311:393–399.  https://doi.org/10.1007/s00441-003-0702-8 Google Scholar
  31. 31.
    Bellamy N, Buchanan W, Goldsmith C et al (1998) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840Google Scholar
  32. 32.
    Bellamy N (1995) Outcome measurement in osteoarthritis clinical trials. J Rheumatol Suppl 43:49–51Google Scholar
  33. 33.
    Bolognese JA, Schnitzer TJ, Ehrich EW (2003) Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthr Cartil 11:499–507.  https://doi.org/10.1016/S1063-4584(03)00082-7 CrossRefGoogle Scholar
  34. 34.
    Saleh KJ, Davis A (2016) Measures for pain and function assessments for patients with osteoarthritis. J Am Acad Orthop Surg 24:e148–e162.  https://doi.org/10.5435/JAAOS-D-16-00303 CrossRefGoogle Scholar
  35. 35.
    McConnell S, Kolopack P, Davis AM (2001) The Western Ontario and McMaster universities osteoarthritis index ( WOMAC ): a review of its utility and measurement properties. Arthritis Rheum 45:453–461CrossRefGoogle Scholar

Copyright information

© SICOT aisbl 2018

Authors and Affiliations

  • Juan Mario García-Coronado
    • 1
  • Lorena Martínez-Olvera
    • 1
  • Rodrigo E. Elizondo-Omaña
    • 1
  • Carlos Alberto Acosta-Olivo
    • 2
  • Félix Vilchez-Cavazos
    • 2
  • Luis Ernesto Simental-Mendía
    • 3
  • Mario Simental-Mendía
    • 2
    Email author
  1. 1.Department of Human Anatomy, Faculty of MedicineUniversidad Autónoma de Nuevo LeónMonterreyMéxico
  2. 2.Orthopedics and Traumatology Service, University Hospital “Dr. José Eleuterio González”Universidad Autónoma de Nuevo LeónMonterreyMéxico
  3. 3.Biomedical Research Unit, Mexican Social Security InstituteDurangoMéxico

Personalised recommendations